List Trials for Recurrent Prostate Cancer

Prostate Cancer

 

Phenelzine Sulfate and Docetaxel Post First-Line Docetaxel Therapy
A Phase II Study of MAOA Inhibitor Plus Docetaxel in Patients Currently Receiving and Progressing on Docetaxel Therapy

Investigator: Evan Yu, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT01253642

Abiraterone Acetate for Metastatic, Castration Resistant Prostate Cancer
Open Label Pharmacodynamic Study of Abiraterone in the Treatment of Metastatic, Castration Resistant Prostate Cancer

Investigator: Robert Bruce Montgomery, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT01508234

Abiraterone Acetate for Metastatic Hormone-Resistant Prostate Cancer (7639)
Open Label Pharmacodynamic Study of Abiraterone in the Treatment of Metastatic, Castration Resistant Prostate Cancer

Investigator: Robert Montgomery, MD;   Conditions: Prostate Cancer;    Status: Closed;   Study ID: NCT01503229

Degarelix Acetate Prior to Radiation Therapy (7846)
Degarelix Acetate Prior to Radiation Therapy

Investigator: Robert Bruce Montgomery, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT01731912

Molecular correlates of sensitivity and resistance to therapy in prostate cancer (UW6932)
Molecular correlates of sensitivity and resistance to therapy in prostate cancer

Investigator: Robert Montgomery, MD;   Conditions: Metastatic Prostate Cancer;    Status: Recruiting;   Study ID: NCT01050504

PASS
Canary Prostate Active Surveillance Study

Investigator: Daniel W. Lin, MD;   Conditions: Prostatic Neoplasms;    Status: Recruiting;   Study ID: NCT00756665

ARN-509 for Relapsed Hormone Sensitive Prostate Cancer (20130917)
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men with Biochemically Relapsed Hormone Sensitive Prostate Cancer

Investigator: Tia Higano, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT01790126

CYT107 With or Without Vaccine Therapy for Metastatic Hormone-Resistant Prostate Cancer (CITN12-03)
A Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) after Completion of Standard FDA Approved therapy with Sipuleucel-T (Provenge®) for Patients with Asymptomatic or Minimally Symptomatic Metastatic Castration-resistant Prostate Cancer (mCRPC)

Investigator: Evan Yu, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT01881867

MOR209/ES414 for Metastatic Castration-Resistant Prostate Cancer (20142613)
A Phase I Study of ES414 In Patients with Metastatic Castration-Resistant Prostate Cancer

Investigator: Tia Higano, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT02262910

Bipolar Androgen Therapy vs. Enzalutamide for Castrate-Resistant Metastatic Prostate Cancer (9342)
A Randomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic Men with Castration Resistant Metastatic Prostate Cancer: The TRANSFORMER Trial (Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance)

Investigator: Michael Schweizer, MD;   Conditions: Prostate Cancer; Castration-Resistant Prostate Cancer (CRPC);    Status: Recruiting;   Study ID: NCT02286921

INO-5150 with or without INO-9012 for Relapsed Prostate Cancer (20152240)
Phase I, Open-Label Trial to Evaluate the Safety and Immunogenicity of INO-5150 Alone or in Combination with INO-9012 in Men with Biochemically Relapsed (PSA) Prostate Cancer

Investigator: Heather Cheng, MD;   Conditions: Prostate Cancer; Solid Tumors;    Status: Recruiting;   Study ID: NCT02514213

Niclosamide with Enzalutamide for Androgen Receptor Splice Variant-Positive, Castration-Resistant Prostate Cancer (9390)
A Phase I Study of Niclosamide in Combination with Enzalutamide in Men with Androgen Receptor Splice Variant Positive Castration-Resistant Prostate Cancer

Investigator: Michael Schweizer;   Conditions: Prostate Cancer; Solid Tumors; Castration-resistant (CRPC);    Status: Recruiting;   Study ID: NCT02532114

AZD8186 Ascending Dose Study for mCRPC (UW13024)
A Phase I, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumorActivity of AZD8186 in Patients with Advanced Castration-resistant Prostate Cancer (CRPC), as Monotherapy and in Combination with Abiraterone Acetate or AZD2014

Investigator: Tia Higano, MD;   Conditions: Advanced Castrate-resistant Prostate Cancer (CRPC);;    Status: Recruiting;   Study ID: NCT01884285

MPDL3280A + Cobimetinib for Locally Advanced or Metastatic Cancer
A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors

Investigator: Laura Chow, MD;   Conditions: Neoplasms;    Status: Closed;   Study ID: NCT01988896

Enzalutamide for Castrate-resistant Prostate Cancer
Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer (CRPC) With Correlative Assessment of Androgen Receptor (AR) Signaling and Whole-exome and Transcriptome Sequencing

Investigator: Robert Bruce Montgomery, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT01942837

ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer (SWOG 1216)
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer

Investigator: Heather H. Cheng, MD, PhD;   Conditions: Prostate Cancer;    Status: Pending;   Study ID: NCT01809691